INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
RL
Corporate insider

Rachlin Evan Lockwood

DirectorCIK 0002151678

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells1 / 0
Max Insider Score49
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
410.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Iambic Therapeutics, Inc.Director · Oct 16, 2026
9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C
—
57.8K sh
Oct 16, 2026
Oct 19, 2026
traded Oct 16, 2026
+3d
SEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

17
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
410.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

49
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Open-market purchase
BUY$11.50M
718.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.15M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
57.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
306.7K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Grant or award
A—
20.3K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence